- Funding announced for vaccine against CWD
The federal and provincial governments are investing up to $1.16 million in Pan-Provincial Vaccine Enterprise to help develop a new vaccine against chronic wasting disease.
- Funding awarded to develop novel RSV and PIV3 vaccines
VIDO-InterVac was recently awarded funding from the Canadian Institutes of Health Research to develop vaccines for respiratory syncytial virus and parainfluenza type 3 viruses.
- A first hand ebola experience
VIDO-InterVac researcher Scott Napper was featured on CTV to highlight the impact of local research on the fight against Ebola.
- Director Andrew Potter's Blog: Why skipping the flu shot is a selfish gamble
Infectious diseases continue to dominate the news, with the threat of Ebola currently in the public eye. However, it is also the start of the flu season in Canada and interestingly there is a common solution to both of these issues: vaccination.
- Ebola concern on the rise for Canadians
VIDO-InterVac Director and CEO, Andrew Potter, was featured on Global News to discuss the global threat of Ebola.
- Worry more about getting flu shot, not Ebola: VIDO
Dr. Andrew Potter was a guest on Global News to provide insight on the risk of Ebola in Saskatoon.
- U of S alumnus and tech helping in fight against Ebola
A suite of tools developed at the University of Saskatchewan is giving researchers new insights into how the Ebola virus, currently epidemic in some parts of Africa, wreaks havoc on its victims.
- VIDO-InterVac 2013-2014 Annual Report released
- Associate Director Paul Hodgson's Biotech Blog: An ounce of prevention
Vaccines are one of the greatest achievements in public health.
- VIDO-InterVac: Leading Vaccine Discovery
Risk Group 3 infectious diseases have the potential to cause serious health and economic consequences. For example, PEDv and MERS have caused recent concerns in North America. To combat these diseases, VIDO built InterVac - a CL3 research lab.